MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive AgreementItem 9.01 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February8, 2018, and the information set forth in such Item 9.01 is incorporated herein by reference.
The Offering was made to the Company’s shelf registration statement on Form S-3, initially filed with the Securities and Exchange Commission (“SEC”) on September22, 2017, which became effective on October2, 2017 (File No.333-220593) and the related prospectus supplement filed with the SEC to Rule 424(b) under the Securities Act.
This Current Report contains forward-looking statements that involve risk and uncertainties, such as the amount of net proceeds expected from the Offering. The risks and uncertainties involved include risks detailed from time to time in the Company’s SEC filings.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
About MEDICINOVA, INC. (NASDAQ:MNOV)
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.
